US Drug Recall Register
Class II · Moderate risk Terminated Initiated Feb 7, 2017 (10 years ago)

Glipizide 2.5 mg ER Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

What was recalled

Glipizide 2.5 mg ER Tablets, Manufactured by Watson Laboratories, Inc., Parsippany, NJ 07054, Repackaged by RemedyRepack, Indiana, PA 15701, NDC 52125-0764-02

Recalling firm
RemedyRepack Inc.
NDC code
52125-0764-02
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0482-2017

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Glipizide recalls

See all
Class II · Moderate risk Terminated

glipiZIDE

Reason Failed Dissolution Specifications:

Amerisource Health Services LLC D-0202-2025
Class II · Moderate risk Terminated

GlipiZIDE Extended-Release Tablets

Reason Failed Dissolution Specifications: results were above specification.

American Health Packaging D-0020-2022
Class II · Moderate risk Terminated

GlipiZIDE Extended-release Tablets

Reason Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.

American Health Packaging D-1276-2019
Class II · Moderate risk Terminated

Glipizide XL

Reason CGMP Deviations; rejected product was used to manufacture final bulk lot

Pfizer Inc. NDC 59762-0541-2 D-0010-2019
Class III · Low risk Terminated

Glipizide Extended-Release Tablets

Reason Failed Moisture Limits: out of specification test results for water content obtained during stability testing.

Teva Pharmaceuticals USA NDC 0591-0844-15 D-1058-2017